Drugs / Human Embryonic Stem Cell-Derived Cardiomyocyte
Human Embryonic Stem Cell-Derived Cardiomyocyte
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05068674 Comparator | Mar 2022 → Oct 2028 expected | left ventricular failure | Joseph C. Wu | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Embryonic Stem Cell-Derived Cardiomyocyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05068674 ↗ |
| Modality | Cell therapy | “new cell therapy approach” NCT05068674 ↗ |